Selected article for: "adaptive innate and disease severity"

Author: Todorović-Raković, Nataša; Whitfield, Jonathan R.
Title: Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease
  • Cord-id: y1e838ay
  • Document date: 2021_7_3
  • ID: y1e838ay
    Snippet: Interferons have prominent roles in various pathophysiological conditions, mostly related to inflammation. Interferon-gamma (IFNγ) was, initially discovered as a potent antiviral agent, over 50 years ago, and has recently garnered renewed interest as a promising factor involved in both innate and adaptive immunity. When new disease epidemics appear such as SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus), IAV (Influenza A virus),
    Document: Interferons have prominent roles in various pathophysiological conditions, mostly related to inflammation. Interferon-gamma (IFNγ) was, initially discovered as a potent antiviral agent, over 50 years ago, and has recently garnered renewed interest as a promising factor involved in both innate and adaptive immunity. When new disease epidemics appear such as SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus), IAV (Influenza A virus), and in particular the current SARS-CoV-2 pandemic, it is especially timely to review the complexity of immune system responses to viral infections. Here we consider the controversial roles of effectors like IFNγ, discussing its actions in immunomodulation and immunotolerance. We explore the possibility that modulation of IFNγ could be used to influence the course of such infections. Importantly, not only could endogenous expression of IFNγ influence the outcome, there are existing IFNγ therapeutics that can readily be applied in the clinic. However, our understanding of the molecular mechanisms controlled by IFNγ suggests that the exact timing for application of IFNγ-based therapeutics could be crucial: it should be earlier to significantly reduce the viral load and thus decrease the overall severity of the disease.

    Search related documents:
    Co phrase search for related documents
    • aberrant ifn and acute respiratory syndrome: 1
    • aberrant ifn and lung injury: 1
    • aberrant ifn and lymphocyte activation: 1
    • accessory protein and acute ards respiratory distress syndrome: 1
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
    • accessory protein and lung damage: 1
    • accessory protein and lung injury: 1, 2
    • accessory protein and lung virus: 1, 2
    • accessory protein and m1 phenotype: 1
    • accessory protein and m1 phenotype macrophage: 1
    • accessory protein and macrophage activation: 1
    • accessory protein and macrophage monocyte: 1
    • accessory protein and macrophage phenotype: 1